Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data

References

• SmolenJSAletahaDMcInnesIBRheumatoid arthritisLancet2016388100552023203827156434
   PubMed Web of Science ®Google Scholar
• TaylorPCMooreAVasilescuRAlvirJTaralloMA structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspectiveRheumatol Int201636568569526746843
   PubMed Web of Science ®Google Scholar
• SmolenJSBreedveldFCBurmesterGRTreating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnn Rheum Dis201675131525969430
   PubMed Web of Science ®Google Scholar
• SullivanSDAlfonso-CristanchoRCarlsonJMallyaURingoldSEconomic consequences of sequencing biologics in rheumatoid arthritis: a systematic reviewJ Med Econ201316339139623298329
   PubMedGoogle Scholar
• GvozdenovićEKoevoetsRLangenhoffJAllaartCfLandewéRBComparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature reviewScand J Rheumatol201443534935524898046
   PubMed Web of Science ®Google Scholar
• KonczTPentekMBrodszkyVErsekKOrlewskaEGulacsiLAdherence to biologic DMARD therapies in rheumatoid arthritisExpert Opin Biol Ther20101091367137820681888
   PubMed Web of Science ®Google Scholar
• FidderHHSingendonkMMvan der HaveMOldenburgBvan OijenMGLow rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic reviewWorld J Gastroenterol201319274344435023885145
   PubMed Web of Science ®Google Scholar
• López-GonzálezRLeónLLozaERedondoMGarcia de YébenesMJCarmonaLAdherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature reviewClin Exp Rheumatol201533455956925602291
   PubMed Web of Science ®Google Scholar
• LeonLRodriguez-RodriguezLRosalesZLong-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practiceScand J Rheumatol201645645646027115843
   PubMed Web of Science ®Google Scholar
• GulácsiLRenczFPoórGPatients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differencesAnn Rheum Dis201675594294326888946
   PubMed Web of Science ®Google Scholar
• BonczISebestyénAFinancial deficits in the health services of the UK and HungaryLancet2006368953991791816962878
   PubMed Web of Science ®Google Scholar
• PeaseCPopeJETruongDComparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapySemin Arthritis Rheum2011411818921168187
   PubMed Web of Science ®Google Scholar
• PutrikPRamiroSKvienTKSokkaTUhligTBoonenAEquity in Clinical Eligibility Criteria for RA treatment Working GroupVariations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth?Ann Rheum Dis201473112010202123940213
   PubMed Web of Science ®Google Scholar
• PéntekMPoórGWilandPBiological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countriesEur J Health Econ201415Suppl 1S35S4324832834
   PubMed Web of Science ®Google Scholar
• RenczFKeményLGajdácsiJZUse of biologics for psoriasis in Central and Eastern European countriesJ Eur Acad Dermatol Venereol201529112222223026370506
   PubMed Web of Science ®Google Scholar
• RenczFPéntekMBortlikMBiological therapy in inflammatory bowel diseases: access in Central and Eastern EuropeWorld J Gastroenterol20152161728173725684937
   PubMed Web of Science ®Google Scholar
• KádárGBalázsESoósBDisease activity after the discontinuation of biological therapy in inflammatory rheumatic diseasesClin Rheumatol201433332933324497172
   PubMed Web of Science ®Google Scholar
• LakiJMónokGPálosiMGajdácsiJZEconomical aspect of biological therapy in inflammatory conditions in HungaryExpert Opin Biol Ther201313332733723163831
   PubMed Web of Science ®Google Scholar
• SullivanSDMauskopfJAAugustovskiFBudget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue Health201417151424438712
   PubMed Web of Science ®Google Scholar
• BrodszkyVBajiPBaloghOPéntekMBudget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countriesEur J Health Econ201415Suppl 1S65S7124832837
   PubMed Web of Science ®Google Scholar
• JhaAUptonADunlopWCAkehurstRThe budget impact of bio-similar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countriesAdv Ther201532874275626343027
   PubMed Web of Science ®Google Scholar
• van RielPLRenskersLThe Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritisClin Exp Rheumatol201634Suppl 101(5)4044
   Web of Science ®Google Scholar
• YeawJWatsonCFoxKMSchabertVFGoodmanSGandraSRTreatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sampleAdv Ther201431441042524604700
   PubMed Web of Science ®Google Scholar
• MeissnerBTrivediDYouMRosenblattLSwitching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world settingJ Med Econ201417425926524575891
   PubMedGoogle Scholar
• BonafedeMFoxKMWatsonCPrincicNGandraSRTreatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settingsAdv Ther201229866467422886712
   PubMed Web of Science ®Google Scholar
• OgaleSHitrayaEHenkHJPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord20111220421929807
   PubMed Web of Science ®Google Scholar
• LiPBlumMAVon FeldtJHennessySDoshiJAAdherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritisValue Health201013680581221054657
   PubMed Web of Science ®Google Scholar
• ChatzidionysiouKAsklingJErikssonJKristensenLEvan Vollen-hovenREffectiveness of TNF inhibitor switch in RA: results from the national Swedish registerAnn Rheum Dis201574589089624431398
   PubMed Web of Science ®Google Scholar
• LequerréTFarranÉMénardJFSwitching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: an observational retrospective study of 72 rheumatoid arthritis switchersJoint Bone Spine201582533033725864942
   PubMed Web of Science ®Google Scholar
• HuizingaTWConaghanPGMartin-MolaEClinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY studyAnn Rheum Dis2015741354325169728
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDRheumatoid arthritis therapy reappraisal: strategies, opportunities and challengesNat Rev Rheumatol201511527628925687177
   PubMed Web of Science ®Google Scholar
• SoutoAManeiroJRGómez-ReinoJJRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesRheumatology (Oxford)201655352353426490106
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLBIOBADASER GroupSwitching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Res Ther200681R2916507128
   PubMed Web of Science ®Google Scholar
• HyrichKLLuntMWatsonKDSymmonsDPSilmanAJBritish Society for Rheumatology Biologics RegisterOutcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort studyArthritis Rheum2007561132017195186
   PubMed Web of Science ®Google Scholar
• Martínez-SantanaVGonzález-SarmientoECalleja-HernándezMSánchez-SánchezTComparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritisPatient Prefer Adherence2013771972724023512
   PubMed Web of Science ®Google Scholar
• BuchMHRubbert-RothAFerraccioliGTo switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50Autoimmun Rev201211855856222037117
   PubMed Web of Science ®Google Scholar
• EmeryPGottenbergJERubbert-RothARituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyAnn Rheum Dis201574697998424442884
   PubMed Web of Science ®Google Scholar
• HishitaniYOgataAShimaYRetention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritisScand J Rheumatol201342425325923470089
   PubMed Web of Science ®Google Scholar
• KoutsianasCThomasKHatzaraCFRI0160 comparative drug survival of different non-anti-TNF IV biologics after anti-TNF failure in rheumatoid arthritis patientsAnn Rheum Dis201574Suppl 2481
   Web of Science ®Google Scholar